Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Commitments and Contingencies (Details Textual)

v3.21.2
Note 7 - Commitments and Contingencies (Details Textual)
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 16, 2020
USD ($)
Jul. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sublease Income     $ 10,000 $ 10,000 $ 31,000 $ 31,000
Operating Lease, Payments     35,000 34,000 103,000 100,000
License Agreements Expense     56,000 61,000 150,000 183,000
Research and Development Expense, Total     4,095,000 4,435,000 11,239,000 10,971,000
MD Anderson [Member]            
Payments For Research And Development Agreement   $ 175,000        
Research and Development Expense, Total     220,000 212,000 498,000 537,000
Houston Pharmaceuticals, Inc [Member]            
Other Commitments, Number of Agreements 2          
Related Party Transaction, Expenses from Transactions with Related Party     $ 59,000 $ 59,000 $ 176,000 $ 226,000
Houston Pharmaceuticals, Inc [Member] | Consulting Agreement on Licensed Molecules [Member]            
Other Commitments, Term (Year) 2 years          
Other Commitment, Total $ 43,500          
Houston Pharmaceuticals, Inc [Member] | Agreement Providing Access to Laboratory Equipment [Member]            
Other Commitment, Total $ 15,000          
Other Commitments, Cancellation Period (Day) 60 days